Search research articles
Contact Us
Filters
Showing results (591-600 of 742) with videos related to
Page
of 75
Sort By:
British Medical Journal
|
March 25, 1978
Ectopic pregnancy rates in IUD users
R Aznar, C L Berry, I D Cooke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
Ryohei Katayama, Luc Friboulet, Sumie Koike, et al.
ESMO Open
|
December 13, 2021
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
J J Lin, A Muzikansky, E Kennedy, et al.
The Journal of Biological Chemistry
|
May 11, 2012
Characterization of Caulobacter crescentus FtsZ protein using dynamic light scattering
Sen Hou, Stefan A Wieczorek, Tomasz S Kaminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E Felip, A T Shaw, A Bearz, et al.
Lung Cancer (Auckland, N.Z.)
|
February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Shirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
JTO Clinical and Research Reports
|
July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
Jaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
ACS Catalysis
|
April 15, 2026
Enantioselective Synthesis of Complex Carbocycles by C-H Insertion of Aryl/Aryl Carbenes
Jose M Ruiz, Dylan R Turner, Mingchun Gao, et al.
Genes & Development
|
March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Alice T Shaw, Alexander Meissner, James A Dowdle, et al.
Page
of 75
Search research articles
Search
Showing results (591-600 of 742) with videos related to
Sort By:
Page
of 75
British Medical Journal
|
March 25, 1978
Ectopic pregnancy rates in IUD users
R Aznar, C L Berry, I D Cooke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
Ryohei Katayama, Luc Friboulet, Sumie Koike, et al.
ESMO Open
|
December 13, 2021
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
J J Lin, A Muzikansky, E Kennedy, et al.
The Journal of Biological Chemistry
|
May 11, 2012
Characterization of Caulobacter crescentus FtsZ protein using dynamic light scattering
Sen Hou, Stefan A Wieczorek, Tomasz S Kaminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
E Felip, A T Shaw, A Bearz, et al.
Lung Cancer (Auckland, N.Z.)
|
February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Shirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
JTO Clinical and Research Reports
|
July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
Jaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
ACS Catalysis
|
April 15, 2026
Enantioselective Synthesis of Complex Carbocycles by C-H Insertion of Aryl/Aryl Carbenes
Jose M Ruiz, Dylan R Turner, Mingchun Gao, et al.
Genes & Development
|
March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Alice T Shaw, Alexander Meissner, James A Dowdle, et al.
Page
of 75